Table 2.
Biomarker status of patients with mCRC treated with 1L bevacizumab-awwb.
| Biomarker a | Naïve patients (n = 129) | Switchers (n = 105) |
|---|---|---|
| KRAS test, n (%) | 105 (81.4%) | 81 (77.1%) |
| KRAS status among tested patients, n (%) | ||
| Positive | 49 (46.7%) | 45 (55.6%) |
| Negative | 53 (50.5%) | 36 (44.4%) |
| Other b | 3 (2.9%) | 0 |
| BRAF test, n (%) | 96 (74.4%) | 74 (70.5%) |
| BRAF status among tested patients, n (%) | ||
| Positive | 13 (13.5%) | 8 (10.8%) |
| Negative | 81 (84.4%) | 66 (89.2%) |
| Other b | 2 (2.1%) | 0 |
| NRAS test, n (%) | 92 (71.3%) | 66 (62.9%) |
| NRAS status among tested patients, n (%) | ||
| Positive | 6 (6.5%) | 4 (6.1%) |
| Negative | 84 (91.3%) | 61 (92.4%) |
| Other c | 2 (2.2%) | 1 (1.5%) |
| MSI test, n (%) | 93 (72.1%) | 69 (65.7%) |
| MSI status among tested patients, n (%) | ||
| Microsatellite instability – high (positive) | 3 (3.2%) | 2 (2.9%) |
| Microsatellite instability – stable (negative) | 86 (92.5%) | 63 (91.3%) |
| Other d | 4 (4.3%) | 4 (5.8%) |
| MMR test, n (%) | 96 (75.2%) | 74 (70.5%) |
| MMR status among tested patients, n (%) | ||
| MMR deficient | 7 (7.2%) | 2 (2.7%) |
| MMR proficient | 89 (91.8%) | 72 (97.3%) |
a
Biomarker results were reported using the medical value that was recorded closest to metastatic CRC diagnosis.
b
Uninterpretable test results.
c
Insufficient quality or equivocal test results.
d
Insufficient quality, equivocal, or undetermined/undocumented test results.
1L, first-line; BRAF, B-rapidly accelerated fibrosarcoma; KRAS, Kirsten rat sarcoma; mCRC, metastatic colorectal cancer; MMR, mismatch repair; MSI, microsatellite instability; NRAS, neuroblastoma rat sarcoma.